Stiripentol (Diacomit — Biocodex SA) indication: severe myoclonic epilepsy in infancy (Dravet syndrome)
Record ID 32015000168
Authors' recomendations: The Canadian Drug Expert Committee (CDEC) recommends that stiripentol be listed for use in combination with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (Dravet syndrome), whose seizures are not adequately controlled with clobazam and valproate alone, if conditions are met.
Project Status: Completed
Year Published: 2014
URL for published report: http://www.cadth.ca/media/cdr/complete/cdr_complete_SR0360_Diacomit_October_20_2014.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Child, Preschool
- Infant, Newborn
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.